efficacy of risperidone augmentation with ondansetron in the treatment of negative and depressive symptoms in schizophrenia: a randomized clinical trial

Authors

roya samadi psychiatry and behavioral sciences research center, psychiatry department, faculty of medicine, mashhad university of medical sciences, mashhad, iran

reza daneshmand substance abuse and dependence research center, university of social welfare and rehabilitation sciences, tehran, iran

shervin assari faculty member of department of psychiatry, school of public health, university of michigan, ann arbor, usa

ali akhoundpour manteghi associated professor at psychiatry department, ibn-e-sina hospital, faculty of medicine, mashhad university of medical sciences, mashhad, iran

abstract

background: given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. methods: in a double-blinded, placebo-controlled, randomized trial (irct registration # 201112125280n7), in 2012–2013 in mashhad, iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. the patients were evaluated using the positive and negative syndrome scale (panss), wechsler’s adult intelligence scale-revised (wais-r), and hamilton’s rating scale for depression (hrsd) at baseline and 12 weeks later. changes in the inventories were used to evaluate the efficacy of the treatment. the t test, chi-square test, and spss (version 16) were used to analyze the data. the statistical significance was set at p<0.05. results: ondansetron plus risperidone was associated with a significantly larger improvement in the panss overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (p<0.001). the wais-r scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. the administration of ondansetron significantly improved visual memory based on the subtests of the wais (p<0.05). ondansetron had no positive effects on depressive symptoms (effect size=0.13). conclusion: this study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. trial registration number: irct201112125280n7

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...

full text

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

BACKGROUND Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. METHODS In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in...

full text

The Therapeutic Effectiveness of Risperidone on Negative Symptoms of Schizophrenia in Comparison with Haloperidol: A Randomized Clinical Trial

Introduction: A number of research studies have shown that the new generation of neuroleptic medications can more effectively contribute to treating negative symptoms of schizophrenia compared with the first generation by influence cognitive functioning. The present study examined the therapeutic effectiveness of manufactured Risperidone and Haloperidol in Iran on treating the negative symptoms...

full text

Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial

Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...

full text

the therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial

introduction: a number of research studies have shown that the new generation of neuroleptic medications can more effectively contribute to treating negative symptoms of schizophrenia compared with the first generation by influence cognitive functioning. the present study examined the therapeutic effectiveness of manufactured risperidone and haloperidol in iran on treating the negative symptoms...

full text

Evaluating the Efficacy of Vitamin D Add-on Therapy on Treatment of Positive, Negative and Cognitive Symptoms in Patients with Chronic Schizophrenia; A Double Blind Clinical Trial

Background: Vitamin D can be effective in treating some symptoms of schizophrenia, and with better control of vitamin D levels and supplementation, there is a potential for reducing this disease. But due to small number of studies, more studies are needed in this area. The aim of this study was to determine the efficacy of vitamin D as an adjunct to the positive, negative, and cognitive symptom...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of medical sciences

جلد ۴۲، شماره ۱، صفحات ۱۴-۰

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023